美国食品药品监督管理局批准了一种新型“表观遗传书写器”抑制剂。 - Suppr

Suppr

超能文献

FDA approves an inhibitor of a novel 'epigenetic writer'.

作者信息

Mullard Asher

出版信息

Nat Rev Drug Discov. 2020 Mar;19(3):156. doi: 10.1038/d41573-020-00024-0.

DOI:10.1038/d41573-020-00024-0

PMID:32127673

Abstract

摘要

相似文献

FDA approves an inhibitor of a novel 'epigenetic writer'.

Nat Rev Drug Discov. 2020 Mar;19(3):156. doi: 10.1038/d41573-020-00024-0.

Janus kinase 2: an epigenetic 'writer' that activates leukemogenic genes.

J Mol Cell Biol. 2010 Oct;2(5):231-3. doi: 10.1093/jmcb/mjp054. Epub 2010 Jan 5.

A kinesthetic motor imagery study in patients with writer' cramp.

Arq Neuropsiquiatr. 2009 Jun;67(2B):396-401. doi: 10.1590/s0004-282x2009000300005.

Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options.

Semin Cancer Biol. 2018 Aug;51:180-197. doi: 10.1016/j.semcancer.2017.07.006. Epub 2017 Aug 2.

FDA notifications. FDA approves Fuzeon, the first fusion inhibitor.

AIDS Alert. 2003 Jun;18(6):78-9.

FDA approves first-in-class SYK inhibitor.

Nat Rev Drug Discov. 2018 May 30;17(6):385. doi: 10.1038/nrd.2018.96.

FDA approves first RET inhibitor.

Nat Biotechnol. 2020 Jun;38(6):662. doi: 10.1038/s41587-020-0568-2.

The FDA approves a first farnesyltransferase inhibitor.

Nat Rev Drug Discov. 2021 Jan;20(1):8. doi: 10.1038/d41573-020-00213-x.

FDA approves first EGFR exon 20 targeted kinase inhibitor.

Nat Rev Drug Discov. 2021 Nov;20(11):806. doi: 10.1038/d41573-021-00168-7.

The DYT1 GAG deletion is infrequent in sporadic and familial writer' s cramp.

Mov Disord. 2000 Nov;15(6):1238-41. doi: 10.1002/1531-8257(200011)15:6<1238::aid-mds1027>3.0.co;2-z.

引用本文的文献

Epigenetic drugs in cancer therapy.

Cancer Metastasis Rev. 2025 Feb 26;44(1):37. doi: 10.1007/s10555-025-10253-7.

Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2.

Eur J Med Chem. 2024 Mar 5;267:116154. doi: 10.1016/j.ejmech.2024.116154. Epub 2024 Jan 26.

Recent advances in developing degraders & inhibitors of lysine methyltransferases.

Curr Opin Chem Biol. 2023 Oct;76:102356. doi: 10.1016/j.cbpa.2023.102356. Epub 2023 Jun 26.

Broad-Spectrum Small-Molecule Inhibitors Targeting the SAM-Binding Site of Flavivirus NS5 Methyltransferase.

ACS Infect Dis. 2023 Jul 14;9(7):1319-1333. doi: 10.1021/acsinfecdis.2c00571. Epub 2023 Jun 22.

New molecular targets in Hodgkin and Reed-Sternberg cells.

Front Immunol. 2023 May 15;14:1155468. doi: 10.3389/fimmu.2023.1155468. eCollection 2023.

A universal fluorescence polarization high throughput screening assay to target the SAM-binding sites of SARS-CoV-2 and other viral methyltransferases.

Emerg Microbes Infect. 2023 Dec;12(1):2204164. doi: 10.1080/22221751.2023.2204164.

Targeting micro-environmental pathways by PROTACs as a therapeutic strategy.

Semin Cancer Biol. 2022 Nov;86(Pt 2):269-279. doi: 10.1016/j.semcancer.2022.07.001. Epub 2022 Jul 4.

G9a: An Emerging Epigenetic Target for Melanoma Therapy.

Epigenomes. 2021 Dec;5(4). doi: 10.3390/epigenomes5040023. Epub 2021 Oct 12.

Polycomb complexes redundantly maintain epidermal stem cell identity during development.

Genes Dev. 2021 Mar 1;35(5-6):354-366. doi: 10.1101/gad.345363.120. Epub 2021 Feb 18.

Genome-Wide Estrogen Receptor Activity in Breast Cancer.

Endocrinology. 2021 Feb 1;162(2). doi: 10.1210/endocr/bqaa224.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

FDA approves an inhibitor of a novel 'epigenetic writer'.

Nat Rev Drug Discov. 2020 Mar;19(3):156. doi: 10.1038/d41573-020-00024-0.

Janus kinase 2: an epigenetic 'writer' that activates leukemogenic genes.

J Mol Cell Biol. 2010 Oct;2(5):231-3. doi: 10.1093/jmcb/mjp054. Epub 2010 Jan 5.

A kinesthetic motor imagery study in patients with writer' cramp.

Arq Neuropsiquiatr. 2009 Jun;67(2B):396-401. doi: 10.1590/s0004-282x2009000300005.

Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options.

Semin Cancer Biol. 2018 Aug;51:180-197. doi: 10.1016/j.semcancer.2017.07.006. Epub 2017 Aug 2.

FDA notifications. FDA approves Fuzeon, the first fusion inhibitor.

AIDS Alert. 2003 Jun;18(6):78-9.

FDA approves first-in-class SYK inhibitor.

Nat Rev Drug Discov. 2018 May 30;17(6):385. doi: 10.1038/nrd.2018.96.

FDA approves first RET inhibitor.

Nat Biotechnol. 2020 Jun;38(6):662. doi: 10.1038/s41587-020-0568-2.

The FDA approves a first farnesyltransferase inhibitor.

Nat Rev Drug Discov. 2021 Jan;20(1):8. doi: 10.1038/d41573-020-00213-x.

FDA approves first EGFR exon 20 targeted kinase inhibitor.

Nat Rev Drug Discov. 2021 Nov;20(11):806. doi: 10.1038/d41573-021-00168-7.

The DYT1 GAG deletion is infrequent in sporadic and familial writer' s cramp.

Mov Disord. 2000 Nov;15(6):1238-41. doi: 10.1002/1531-8257(200011)15:6<1238::aid-mds1027>3.0.co;2-z.

引用本文的文献

Epigenetic drugs in cancer therapy.

Cancer Metastasis Rev. 2025 Feb 26;44(1):37. doi: 10.1007/s10555-025-10253-7.

Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2.

Eur J Med Chem. 2024 Mar 5;267:116154. doi: 10.1016/j.ejmech.2024.116154. Epub 2024 Jan 26.

Recent advances in developing degraders & inhibitors of lysine methyltransferases.

Curr Opin Chem Biol. 2023 Oct;76:102356. doi: 10.1016/j.cbpa.2023.102356. Epub 2023 Jun 26.

Broad-Spectrum Small-Molecule Inhibitors Targeting the SAM-Binding Site of Flavivirus NS5 Methyltransferase.

ACS Infect Dis. 2023 Jul 14;9(7):1319-1333. doi: 10.1021/acsinfecdis.2c00571. Epub 2023 Jun 22.

New molecular targets in Hodgkin and Reed-Sternberg cells.

Front Immunol. 2023 May 15;14:1155468. doi: 10.3389/fimmu.2023.1155468. eCollection 2023.

A universal fluorescence polarization high throughput screening assay to target the SAM-binding sites of SARS-CoV-2 and other viral methyltransferases.

Emerg Microbes Infect. 2023 Dec;12(1):2204164. doi: 10.1080/22221751.2023.2204164.

Targeting micro-environmental pathways by PROTACs as a therapeutic strategy.

Semin Cancer Biol. 2022 Nov;86(Pt 2):269-279. doi: 10.1016/j.semcancer.2022.07.001. Epub 2022 Jul 4.

G9a: An Emerging Epigenetic Target for Melanoma Therapy.

Epigenomes. 2021 Dec;5(4). doi: 10.3390/epigenomes5040023. Epub 2021 Oct 12.

Polycomb complexes redundantly maintain epidermal stem cell identity during development.

Genes Dev. 2021 Mar 1;35(5-6):354-366. doi: 10.1101/gad.345363.120. Epub 2021 Feb 18.

Genome-Wide Estrogen Receptor Activity in Breast Cancer.

Endocrinology. 2021 Feb 1;162(2). doi: 10.1210/endocr/bqaa224.